RYTM Earnings & Financial Statements
Rhythm Pharmaceuticals, Inc.
$86.71
+$0.10(+0.12%)
45
Overall
40
Value
18
Tech
78
Quality
Market Cap
$5.97B
Volume
585.84K
52W Range
$74.50 - $122.20
Target Price
$140.00
RYTM earnings and financial statements: Rhythm Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RYTM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $189.76M | $130.13M | $77.43M | $23.64M | $3.15M |
| Cost of revenue | $19.49M | $13.37M | $9.30M | $2.13M | $599.0K |
| Operating income | -$192.02M | -$265.50M | -$184.36M | -$179.16M | -$170.06M |
| EBITDA | -$175.46M | -$239.65M | -$170.22M | -$171.17M | -$68.45M |
| Net income | -$196.54M | -$260.60M | -$184.68M | -$181.12M | -$69.61M |
| EPS (diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $480.20M | $392.27M | $332.75M | $382.48M | $329.52M |
| Total liabilities | $210.17M | $227.72M | $162.99M | $118.22M | $45.37M |
| Shareholders’ equity | $139.07M | $21.73M | $169.76M | $264.26M | $284.15M |
| Cash and equivalents | $54.30M | $89.14M | $60.08M | $127.68M | $59.25M |
| Long-term debt | $104.24M | $112.21M | $106.63M | $1.26M | $1.95M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$115.67M | -$113.88M | -$136.16M | -$173.43M | -$146.00M |
| Capital expenditure | -$40.95M | -$40.50M | -$47.0K | -$4.28M | -$5.43M |
| Free cash flow | -$156.63M | -$154.38M | -$141.87M | -$177.71M | -$151.44M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RYTM | $86.71 | +0.1% | 585.84K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Rhythm Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW